Cornerstone Advisors (Washington)’s Sarepta Therapeutics SRPT Stock Holding History

Cornerstone Advisors (Washington)’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$82K	Sell	586 -32	-5%	-$4.86K	0.01%	196
2020 Q2	$99K	Sell	618 -44	-7%	-$5.99K	0.01%	170
2020 Q1	$65K	Buy	662 +156	+31%	+$17.8K	0.01%	187
2019 Q4	$65K	Buy	506 +174	+52%	+$17.6K	0.01%	205
2019 Q3	$25K	Sell	332 -25	-7%	-$2.95K	﹤0.01%	316
2019 Q2	$54K	Buy	357 +25	+8%	+$3.04K	0.01%	382
2019 Q1	$40K	Buy	332 +67	+25%	+$8.61K	﹤0.01%	430
2018 Q4	$29K	Buy	265 +110	+71%	+$13.8K	0.01%	428
2018 Q3	$25K	Buy	+155	New	+$21.2K	0.02%	488

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Cornerstone Advisors (Washington)'s SRPT Position: Q3 2020 in Review

Cornerstone Advisors (Washington) reduced its Sarepta Therapeutics (SRPT) stake by 5.2% in Q3 2020, selling an estimated $4.86K and leaving 586 shares worth $82K. The position accounts for 0.01% of the portfolio, ranked #196.

Cornerstone Advisors (Washington) first reported a position in SRPT in Q3 2018 and has held it in 9 quarters since. The position peaked at $99K in Q2 2020. 404 funds tracked by Wall St. Rank hold SRPT as of Q3 2020.

Cornerstone Advisors (Washington) held 586 shares of Sarepta Therapeutics worth $82K as of Q3 2020.
Cornerstone Advisors (Washington) sold 32 Sarepta Therapeutics shares in Q3 2020, an estimated $4.86K.
Sarepta Therapeutics made up 0.01% of Cornerstone Advisors (Washington)'s portfolio in Q3 2020, its #196 holding.
Cornerstone Advisors (Washington) first reported a position in Sarepta Therapeutics in Q3 2018 and has held it in 9 quarters since.
Cornerstone Advisors (Washington)'s Sarepta Therapeutics position peaked at $99K in Q2 2020.
404 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2020.

Based on Cornerstone Advisors (Washington)'s 13F filing for Q3 2020, filed 20 Oct 2020.